A groundbreaking development in the realm of cancer immunotherapy has emerged from recent clinical investigations: a novel vaccine engineered to activate the immune system against one of the most pervasive oncogenic drivers, the KRAS mutation. This innovative therapeutic approach has showcased promising preliminary results in patients battling pancreatic ductal adenocarcinoma and colorectal cancer—two malignancies notoriously resistant to existing treatment modalities. Researchers affiliated with the UCLA Health Jonsson Comprehensive Cancer Center, in collaboration with other leading institutions, have spearheaded this study, offering new hope in the fight against these formidable cancers.
At the center of this advancement is a vaccine designated ELI-002 2P, which leverages sophisticated immunological principles to provoke a targeted and enduring anti-tumor immune response. The vaccine is designed to stimulate T cell populations specifically reactive to mutated KRAS epitopes, thereby rallying the body’s own defenses to identify and eradicate residual malignant cells. The clinical data, as reported in the prestigious journal Nature Medicine, reveals that after a median follow-up period of nearly 20 months, patients receiving ELI-002 2P experienced median relapse-free survival of over 16 months and median overall survival approaching 29 months—outperforming historical survival benchmarks for these patient populations.
This therapeutic platform is particularly noteworthy due to its capacity to elicit robust T cell immunity without necessitating the complexities inherent to fully personalized cancer vaccines. Historically, the heterogeneity and complexity of tumor neoantigens compounded the challenge of crafting effective, individualized vaccines within viable time frames. ELI-002 2P circumvents these obstacles through a standardized “off-the-shelf” formulation that capitalizes on amphiphile technology—a proprietary delivery mechanism engineered by Elicio Therapeutics—that directs vaccine components efficiently to lymph nodes. This lymphatic targeting is critical, as lymph nodes serve as immunological hubs where antigen presentation and T cell priming occur, thereby maximizing vaccine immunogenicity.
.adsslot_Zlb4Agh37t{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_Zlb4Agh37t{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_Zlb4Agh37t{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
The Phase 1 AMPLIFY 201 trial forms the empirical foundation for these findings and enrolled twenty-five patients diagnosed with either pancreatic ductal adenocarcinoma or colorectal cancer, all of whom had undergone surgical resection and displayed molecular indicators of minimal residual disease. The presence of circulating tumor DNA (ctDNA) served as a biomarker signaling impending relapse, providing a compelling rationale for administering adjuvant immunotherapy aimed at eradicating microscopic disease reservoirs. The administration protocol involved repeated injections of ELI-002 2P, designed to sustain and amplify the immune response against mKRAS epitopes over time.
Immunological analyses demonstrated that 84% of the treated cohort mounted measurable mKRAS-specific T cell responses encompassing both CD4+ helper and CD8+ cytotoxic subsets. Remarkably, a subset of these T cells exhibited persistence during extended follow-up, reflecting durable immunological memory—a crucial feature for sustained tumor surveillance. This is particularly important given the stealthy nature of minimal residual disease that can seed relapse months or years after apparent clinical remission.
An intriguing facet of the vaccine’s efficacy lies in its impact on measurable molecular disease markers. Approximately one-quarter of patients experienced complete clearance of tumor-associated biomarkers, suggesting effective immune-mediated elimination of residual cancer cells. This finding underscores the vaccine’s potential not only for therapeutic intervention but also as a tool for modifying the natural history of KRAS-driven malignancies, which often have an aggressive clinical course and limited treatment options.
Survival analyses further accentuated the correlation between immune response magnitude and clinical benefit. Patients whose T cell activity surpassed predefined thresholds demonstrated prolonged relapse-free and overall survival compared to those with suboptimal immune responses. In fact, median relapse-free survival in the high-response group was not reached within the observation window, contrasting starkly with a relapse-free survival median of just over three months in the low-response group. This statistically significant disparity reinforces the vaccine’s immunological mechanism of action as a pivotal determinant of therapeutic success.
Moreover, the breadth of the anti-tumor immune response elicited by ELI-002 2P was expanded beyond KRAS mutations. Over two-thirds of patients exhibited immune reactivity against additional tumor-associated antigens, implying the vaccine may catalyze epitope spreading—a phenomenon wherein the immune system begins to recognize a wider array of tumor neoantigens. This could potentially translate into a more comprehensive eradication of tumor cell variants and reduce the likelihood of immune escape.
Targeting KRAS mutations has posed a formidable challenge historically, owing to the protein’s intracellular location and the difficulty of disrupting its function with conventional agents. The development of ELI-002 2P brings a novel modality to this arena—stimulating T cells to nullify KRAS-driven oncogenesis through immune-mediated cytotoxicity rather than direct enzymatic inhibition. This immunologic strategy holds the promise of overcoming inherent drug resistance and heterogeneity characteristic of KRAS-mutated cancers.
The promising results from this early-phase trial have propelled the research team to initiate a larger Phase 2 study featuring ELI-002 7P, an evolved formulation designed to interrogate a broader spectrum of KRAS mutations. This next-generation vaccine aims to harness the immunotherapeutic momentum garnered thus far to extend benefits to a wider patient population, potentially establishing a new standard of care for KRAS-driven cancers.
The multidisciplinary collaboration behind the research features prominent oncologists and scientists including Zev Wainberg, MD of UCLA Health, with senior contributions from Shubham Pant at MD Anderson Cancer Center and Eileen O’Reilly at Memorial Sloan Kettering Cancer Center. The study encapsulates a significant stride in the paradigm shift toward leveraging immunotherapy for molecularly defined cancer subsets, especially those historically refractory to treatment.
The study was funded by Elicio Therapeutics, whose proprietary amphiphile technology underpins the vaccine’s unique lymph node delivery system. By facilitating direct antigen trafficking to lymphoid tissue, this delivery modality optimizes immunogenicity while preserving a favorable safety profile, as observed in the clinical trial cohort. The ability to generate strong, persistent immune responses with manageable adverse effects is a critical advancement in oncologic vaccine design.
In summary, ELI-002 2P represents a pioneering approach in cancer vaccine development—demonstrating compelling clinical benefit through durable and specific immune targeting of KRAS mutations in pancreatic and colorectal cancers. Its potential to transform the therapeutic landscape by improving relapse-free and overall survival offers a beacon of hope for patients diagnosed with these aggressive malignancies. As research progresses into its next phases, the oncology community awaits validation of these findings in larger cohorts, while envisioning a future wherein standardized vaccines reshape cancer treatment protocols.
Subject of Research: KRAS-mutated pancreatic and colorectal cancer immunotherapy
Article Title: (Not provided)
News Publication Date: (Not provided)
Web References:
https://www.nature.com/articles/s41591-025-03876-4
http://dx.doi.org/10.1038/s41591-025-03876-4
References:
The study published in Nature Medicine, DOI: 10.1038/s41591-025-03876-4
Image Credits: (Not provided)
Keywords:
Pancreatic cancer, Colorectal cancer, Cancer immunology, Vaccine research, Vaccine development, KRAS mutation, Cancer vaccine, Immunotherapy, Minimal residual disease, T cell response
Tags: cancer immunotherapyClinical Trials in Oncologycolorectal cancer treatmentELI-002 2P vaccineimmune response activationKRAS mutation targetingnovel cancer treatmentspancreatic cancer vaccinerelapse-free survival in cancer patientsT cell therapy for cancertargeted cancer therapiesUCLA Health cancer research
